Stem cell-based therapy for COVID-19 and ARDS: a systematic review

Abstract Despite global efforts to establish effective interventions for coronavirus disease 2019 (COVID-19) and its major complications, such as acute respiratory distress syndrome (ARDS), the treatment remains mainly supportive. Hence, identifying an effective and safe therapy for severe COVID-19...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gabriele Zanirati, Laura Provenzi, Lucas Lobraico Libermann, Sabrina Comin Bizotto, Isadora Machado Ghilardi, Daniel Rodrigo Marinowic, Ashok K. Shetty, Jaderson Costa Da Costa
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/be44813379604b6997d19051a1aa8d11
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be44813379604b6997d19051a1aa8d11
record_format	dspace
spelling	oai:doaj.org-article:be44813379604b6997d19051a1aa8d112021-11-14T12:39:15ZStem cell-based therapy for COVID-19 and ARDS: a systematic review10.1038/s41536-021-00181-92057-3995https://doaj.org/article/be44813379604b6997d19051a1aa8d112021-11-01T00:00:00Zhttps://doi.org/10.1038/s41536-021-00181-9https://doaj.org/toc/2057-3995Abstract Despite global efforts to establish effective interventions for coronavirus disease 2019 (COVID-19) and its major complications, such as acute respiratory distress syndrome (ARDS), the treatment remains mainly supportive. Hence, identifying an effective and safe therapy for severe COVID-19 is critical for saving lives. A significant number of cell-based therapies have been through clinical investigation. In this study, we performed a systematic review of clinical studies investigating different types of stem cells as treatments for COVID-19 and ARDS to evaluate the safety and potential efficacy of cell therapy. The literature search was performed using PubMed, Embase, and Scopus. Among the 29 studies, there were eight case reports, five Phase I clinical trials, four pilot studies, two Phase II clinical trials, one cohort, and one case series. Among the clinical studies, 21 studies used cell therapy to treat COVID-19, while eight studies investigated cell therapy as a treatment for ARDS. Most of these (75%) used mesenchymal stem cells (MSCs) to treat COVID-19 and ARDS. Findings from the analyzed articles indicate a positive impact of stem cell therapy on crucial immunological and inflammatory processes that lead to lung injury in COVID-19 and ARDS patients. Additionally, among the studies, there were no reported deaths causally linked to cell therapy. In addition to standard care treatments concerning COVID-19 management, there has been supportive evidence towards adjuvant therapies to reduce mortality rates and improve recovery of care treatment. Therefore, MSCs treatment could be considered a potential candidate for adjuvant therapy in moderate-to-severe COVID-19 cases and compassionate use.Gabriele ZaniratiLaura ProvenziLucas Lobraico LibermannSabrina Comin BizottoIsadora Machado GhilardiDaniel Rodrigo MarinowicAshok K. ShettyJaderson Costa Da CostaNature PortfolioarticleMedicineRENnpj Regenerative Medicine, Vol 6, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Gabriele Zanirati Laura Provenzi Lucas Lobraico Libermann Sabrina Comin Bizotto Isadora Machado Ghilardi Daniel Rodrigo Marinowic Ashok K. Shetty Jaderson Costa Da Costa Stem cell-based therapy for COVID-19 and ARDS: a systematic review
description	Abstract Despite global efforts to establish effective interventions for coronavirus disease 2019 (COVID-19) and its major complications, such as acute respiratory distress syndrome (ARDS), the treatment remains mainly supportive. Hence, identifying an effective and safe therapy for severe COVID-19 is critical for saving lives. A significant number of cell-based therapies have been through clinical investigation. In this study, we performed a systematic review of clinical studies investigating different types of stem cells as treatments for COVID-19 and ARDS to evaluate the safety and potential efficacy of cell therapy. The literature search was performed using PubMed, Embase, and Scopus. Among the 29 studies, there were eight case reports, five Phase I clinical trials, four pilot studies, two Phase II clinical trials, one cohort, and one case series. Among the clinical studies, 21 studies used cell therapy to treat COVID-19, while eight studies investigated cell therapy as a treatment for ARDS. Most of these (75%) used mesenchymal stem cells (MSCs) to treat COVID-19 and ARDS. Findings from the analyzed articles indicate a positive impact of stem cell therapy on crucial immunological and inflammatory processes that lead to lung injury in COVID-19 and ARDS patients. Additionally, among the studies, there were no reported deaths causally linked to cell therapy. In addition to standard care treatments concerning COVID-19 management, there has been supportive evidence towards adjuvant therapies to reduce mortality rates and improve recovery of care treatment. Therefore, MSCs treatment could be considered a potential candidate for adjuvant therapy in moderate-to-severe COVID-19 cases and compassionate use.
format	article
author	Gabriele Zanirati Laura Provenzi Lucas Lobraico Libermann Sabrina Comin Bizotto Isadora Machado Ghilardi Daniel Rodrigo Marinowic Ashok K. Shetty Jaderson Costa Da Costa
author_facet	Gabriele Zanirati Laura Provenzi Lucas Lobraico Libermann Sabrina Comin Bizotto Isadora Machado Ghilardi Daniel Rodrigo Marinowic Ashok K. Shetty Jaderson Costa Da Costa
author_sort	Gabriele Zanirati
title	Stem cell-based therapy for COVID-19 and ARDS: a systematic review
title_short	Stem cell-based therapy for COVID-19 and ARDS: a systematic review
title_full	Stem cell-based therapy for COVID-19 and ARDS: a systematic review
title_fullStr	Stem cell-based therapy for COVID-19 and ARDS: a systematic review
title_full_unstemmed	Stem cell-based therapy for COVID-19 and ARDS: a systematic review
title_sort	stem cell-based therapy for covid-19 and ards: a systematic review
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/be44813379604b6997d19051a1aa8d11
work_keys_str_mv	AT gabrielezanirati stemcellbasedtherapyforcovid19andardsasystematicreview AT lauraprovenzi stemcellbasedtherapyforcovid19andardsasystematicreview AT lucaslobraicolibermann stemcellbasedtherapyforcovid19andardsasystematicreview AT sabrinacominbizotto stemcellbasedtherapyforcovid19andardsasystematicreview AT isadoramachadoghilardi stemcellbasedtherapyforcovid19andardsasystematicreview AT danielrodrigomarinowic stemcellbasedtherapyforcovid19andardsasystematicreview AT ashokkshetty stemcellbasedtherapyforcovid19andardsasystematicreview AT jadersoncostadacosta stemcellbasedtherapyforcovid19andardsasystematicreview
_version_	1718429128622866432

Stem cell-based therapy for COVID-19 and ARDS: a systematic review

Ejemplares similares